studies

mNSCLC - L1 - PDL1 positive, anti-PD-(L)1 vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsCheckMate 026 (PDL1>1%), 2016 1.07 [0.86; 1.33] CheckMate 026 (PDL1>5%), 2016 1.02 [0.80; 1.30] EMPOWER lung1 (PDL1>50%), 2021 0.57 [0.42; 0.77] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.83 [0.65; 1.06] IMpower-110 (TC2/3 or IC2/3), 2020 0.72 [0.52; 0.99] IMpower-110 (TC3 or IC3), 2020 0.59 [0.40; 0.88] KEYNOTE-024 (PDL1>50%), 2016 0.60 [0.41; 0.88] KEYNOTE-042 (PDL1>1%), 2019 0.81 [0.71; 0.93] KEYNOTE-042 (PDL1>20%), 2019 0.77 [0.64; 0.92] KEYNOTE-042 (PDL1>50%), 2019 0.69 [0.56; 0.85] KEYNOTE-598, 2020 1.08 [0.85; 1.37] MYSTIC (D ; PDL1>25%), 2020 0.76 [0.56; 1.03] 0.80[0.71; 0.89]CheckMate 026 (PDL1>1%), 2016, CheckMate 026 (PDL1>5%), 2016, EMPOWER lung1 (PDL1>50%), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-598, 2020, MYSTIC (D ; PDL1>25%), 20201261%6,503moderatelow deaths (OS) (extension)detailed resultsIMpower-110 (TC3 or IC3), 2020 0.76 [0.53; 1.08] KEYNOTE-024 (PDL1>50%), 2016 0.62 [0.48; 0.81] KEYNOTE-042 (PDL1>1%), 2019 0.80 [0.71; 0.90] KEYNOTE-042 (PDL1>20%), 2019 0.75 [0.64; 0.88] KEYNOTE-042 (PDL1>50%), 2019 0.98 [0.82; 1.18] 0.79[0.69; 0.90]IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019556%3,201moderatenot evaluable PFS (extension)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.72 [0.60; 0.86] IMpower-110 (TC2/3 or IC2/3), 2020 0.64 [0.50; 0.82] IMpower-110 (TC3 or IC3), 2020 0.59 [0.43; 0.81] KEYNOTE-024 (PDL1>50%), 2016 0.50 [0.39; 0.65] KEYNOTE-042 (PDL1>1%), 2019 1.05 [0.93; 1.18] KEYNOTE-042 (PDL1>20%), 2019 0.95 [0.82; 1.10] KEYNOTE-042 (PDL1>50%), 2019 0.85 [0.71; 1.01] 0.75[0.62; 0.91]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019786%4,083moderateserious progression or deaths (PFS)detailed resultsCheckMate 026 (PDL1>1%), 2016 1.17 [0.95; 1.44] CheckMate 026 (PDL1>5%), 2016 1.15 [0.91; 1.45] EMPOWER lung1 (PDL1>50%), 2021 0.54 [0.43; 0.68] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.77 [0.63; 0.94] IMpower-110 (TC2/3 or IC2/3), 2020 0.67 [0.52; 0.87] IMpower-110 (TC3 or IC3), 2020 0.63 [0.45; 0.88] KEYNOTE-024 (PDL1>50%), 2016 0.50 [0.37; 0.68] KEYNOTE-042 (PDL1>1%), 2019 1.07 [0.94; 1.21] KEYNOTE-042 (PDL1>20%), 2019 0.94 [0.80; 1.11] KEYNOTE-042 (PDL1>50%), 2019 0.81 [0.67; 0.98] KEYNOTE-598, 2020 1.06 [0.86; 1.30] MYSTIC (D ; PDL1>25%), 2020 0.87 [0.59; 1.29] 0.83[0.71; 0.97]CheckMate 026 (PDL1>1%), 2016, CheckMate 026 (PDL1>5%), 2016, EMPOWER lung1 (PDL1>50%), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-598, 2020, MYSTIC (D ; PDL1>25%), 20201283%6,503moderatecritical objective responses (ORR)detailed resultsCheckMate 026 (PDL1>5%), 2016 0.70 [0.46; 1.06] EMPOWER lung1 (PDL1>50%), 2021 2.53 [1.32; 4.85] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.89 [0.62; 1.27] IMpower-110 (TC2/3 or IC2/3), 2020 0.94 [0.59; 1.50] IMpower-110 (TC3 or IC3), 2020 1.55 [0.86; 2.79] KEYNOTE-024 (PDL1>50%), 2016 2.11 [1.31; 3.39] KEYNOTE-042 (PDL1>1%), 2019 1.04 [0.81; 1.33] KEYNOTE-042 (PDL1>20%), 2019 1.24 [0.92; 1.66] KEYNOTE-042 (PDL1>50%), 2019 1.39 [0.99; 1.94] KEYNOTE-598, 2020 1.00 [0.72; 1.39] MYSTIC (D ; PDL1>25%), 2020 0.91 [0.58; 1.43] 1.15[0.96; 1.39]CheckMate 026 (PDL1>5%), 2016, EMPOWER lung1 (PDL1>50%), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-598, 2020, MYSTIC (D ; PDL1>25%), 20201159%5,962moderatelow objective responses (ORR) (extension)detailed resultsIMpower-110 (TC3 or IC3), 2020 1.68 [0.94; 3.01] KEYNOTE-024 (PDL1>50%), 2016 1.89 [1.19; 3.02] KEYNOTE-042 (PDL1>1%), 2019 1.03 [0.81; 1.32] KEYNOTE-042 (PDL1>20%), 2019 1.21 [0.90; 1.62] KEYNOTE-042 (PDL1>50%), 2019 1.35 [0.96; 1.88] 1.30[1.06; 1.59]IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019539%3,201moderateserious AE (any grade)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.52 [0.27; 1.01] MYSTIC (D ; PDL1>25%), 2020 0.42 [0.14; 1.22] 0.49[0.28; 0.86]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, MYSTIC (D ; PDL1>25%), 202020%863moderatenot evaluable AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.39 [0.27; 0.55] MYSTIC (D ; PDL1>25%), 2020 0.91 [0.58; 1.41] 0.59[0.26; 1.35]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, MYSTIC (D ; PDL1>25%), 2020288%863moderatenot evaluable AE leading to death (grade 5)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.39; 2.15] MYSTIC (D ; PDL1>25%), 2020 0.75 [0.20; 2.86] 0.87[0.42; 1.78]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, MYSTIC (D ; PDL1>25%), 202020%863moderatenot evaluable AE leading to treatment discontinuation (any grade)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.34 [0.19; 0.61] MYSTIC (D ; PDL1>25%), 2020 0.75 [0.38; 1.46] 0.50[0.23; 1.07]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, MYSTIC (D ; PDL1>25%), 2020267%863moderatenot evaluable SAE (any grade)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.99 [0.68; 1.44] MYSTIC (D ; PDL1>25%), 2020 1.22 [0.77; 1.94] 1.07[0.80; 1.44]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, MYSTIC (D ; PDL1>25%), 202020%863moderatenot evaluable STRAE (any grade)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.93 [0.60; 1.46] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.50 [0.29; 0.85] KEYNOTE-024 (PDL1>50%), 2016 1.05 [0.60; 1.82] MYSTIC (D ; PDL1>25%), 2020 0.38 [0.18; 0.77] 0.68[0.43; 1.07]CheckMate 026 (PDL1>1%), 2016, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, MYSTIC (D ; PDL1>25%), 2020463%1,697moderatenot evaluable STRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.82 [0.50; 1.33] KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.55; 1.72] 0.88[0.61; 1.27]CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 201620%834moderatenot evaluable TRAE (any grade)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.20 [0.12; 0.34] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.27 [0.18; 0.40] KEYNOTE-024 (PDL1>50%), 2016 0.31 [0.16; 0.58] KEYNOTE-042 (PDL1>1%), 2019 0.19 [0.14; 0.26] MYSTIC (D ; PDL1>25%), 2020 0.21 [0.12; 0.38] 0.22[0.18; 0.27]CheckMate 026 (PDL1>1%), 2016, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; PDL1>25%), 202050%2,948moderatenot evaluable TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.21 [0.14; 0.31] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.19 [0.12; 0.29] KEYNOTE-024 (PDL1>50%), 2016 0.32 [0.20; 0.51] KEYNOTE-042 (PDL1>1%), 2019 0.30 [0.23; 0.39] MYSTIC (D ; PDL1>25%), 2020 0.36 [0.22; 0.61] 0.26[0.21; 0.33]CheckMate 026 (PDL1>1%), 2016, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; PDL1>25%), 2020539%2,948moderatenot evaluable TRAE leading to death (grade 5)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.46 [0.02; 13.73] KEYNOTE-024 (PDL1>50%), 2016 0.32 [0.03; 3.11] KEYNOTE-042 (PDL1>1%), 2019 0.90 [0.42; 1.92] MYSTIC (D ; PDL1>25%), 2020 0.95 [0.06; 15.32] 0.80[0.40; 1.58]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; PDL1>25%), 202040%2,418moderatenot evaluable TRAE leading to discontinuation (any grade)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.70 [0.41; 1.20] KEYNOTE-024 (PDL1>50%), 2016 0.64 [0.29; 1.44] KEYNOTE-042 (PDL1>1%), 2019 0.95 [0.64; 1.39] MYSTIC (D ; PDL1>25%), 2020 0.47 [0.21; 1.04] 0.77[0.59; 1.01]CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; PDL1>25%), 202040%2,399moderatenot evaluable TRAE leading to discontinuation (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 1.24 [0.64; 2.40] KEYNOTE-024 (PDL1>50%), 2016 0.86 [0.32; 2.29] KEYNOTE-042 (PDL1>1%), 2019 1.09 [0.71; 1.66] 1.09[0.78; 1.53]CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201930%2,085moderatenot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 3.88 [0.17; 86.15] 3.88[0.17; 86.15]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Alopecia TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83] KEYNOTE-042 (PDL1>1%), 2019 0.07 [0.00; 1.21] 0.18[0.01; 2.28]CheckMate 026 (PDL1>1%), 2016, KEYNOTE-042 (PDL1>1%), 2019214%1,781moderatenot evaluable Anaemia TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.02 [0.00; 0.13] KEYNOTE-024 (PDL1>50%), 2016 0.08 [0.02; 0.28] KEYNOTE-042 (PDL1>1%), 2019 0.04 [0.02; 0.12] 0.05[0.02; 0.10]CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201930%2,085moderatenot evaluable Arthralgia TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81] 0.97[0.02; 48.81]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.12 [0.01; 2.31] KEYNOTE-042 (PDL1>1%), 2019 0.29 [0.08; 1.05] 0.25[0.08; 0.82]CheckMate 026 (PDL1>1%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,781moderatenot evaluable Blood creatinine increased TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09] KEYNOTE-024 (PDL1>50%), 2016 0.49 [0.02; 14.58] 0.98[0.09; 10.85]CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 201620%834moderatenot evaluable Colitis TRAE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36] KEYNOTE-024 (PDL1>50%), 2016 3.93 [0.18; 87.97] KEYNOTE-042 (PDL1>1%), 2019 3.89 [0.43; 34.87] 3.85[0.82; 18.18]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201930%2,104moderatenot evaluable Constipation TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83] KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81] 0.98[0.10; 9.40]CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201930%2,085moderatenot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.24 [0.03; 2.19] KEYNOTE-024 (PDL1>50%), 2016 0.12 [0.01; 2.27] KEYNOTE-042 (PDL1>1%), 2019 0.53 [0.18; 1.60] 0.40[0.16; 1.01]CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201930%2,085moderatenot evaluable Diabetes TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69] 1.95[0.07; 58.69]KEYNOTE-024 (PDL1>50%), 201610%304NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.59 [0.14; 2.48] KEYNOTE-024 (PDL1>50%), 2016 3.00 [0.60; 15.11] KEYNOTE-042 (PDL1>1%), 2019 4.87 [0.57; 41.77] 1.77[0.48; 6.46]CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019342%2,085moderatenot evaluable Dysgeusia TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83] KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] 0.98[0.06; 15.72]CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 201620%834moderatenot evaluable Fatigue TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.20 [0.06; 0.71] KEYNOTE-024 (PDL1>50%), 2016 0.38 [0.07; 2.00] KEYNOTE-042 (PDL1>1%), 2019 0.36 [0.09; 1.36] 0.29[0.13; 0.64]CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201930%2,085moderatenot evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed resultsCheckMate 026 (PDL1>1%), 2016 1.19 [0.36; 3.94] 1.19[0.36; 3.94]CheckMate 026 (PDL1>1%), 201610%530NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 11.47 [1.48; 88.87] KEYNOTE-042 (PDL1>1%), 2019 13.68 [0.77; 241.54] 12.17[2.30; 64.46]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-042 (PDL1>1%), 201920%1,800moderatenot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51] KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80] 1.26[0.15; 10.81]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201930%2,104moderatenot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69] KEYNOTE-042 (PDL1>1%), 2019 5.82 [0.29; 116.52] 3.62[0.38; 34.25]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51] KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80] 1.19[0.18; 7.84]CheckMate 026 (PDL1>1%), 2016, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201940%2,634moderatenot evaluable Increase AST TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 1.94 [0.35; 10.63] 1.94[0.35; 10.63]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 3.51 [0.72; 17.07] KEYNOTE-042 (PDL1>1%), 2019 1.75 [0.58; 5.26] 2.20[0.89; 5.42]CheckMate 026 (PDL1>1%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,781moderatenot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51] KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] KEYNOTE-042 (PDL1>1%), 2019 0.16 [0.02; 1.33] 0.31[0.06; 1.66]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201930%2,104moderatenot evaluable Leucopenia TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.05 [0.00; 0.92] KEYNOTE-042 (PDL1>1%), 2019 0.05 [0.00; 0.82] 0.05[0.01; 0.38]CheckMate 026 (PDL1>1%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,781moderatenot evaluable Maculopapular rash TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09] 1.97[0.07; 59.09]CheckMate 026 (PDL1>1%), 201610%530NAnot evaluable Mucosal inflammation TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83] 0.98[0.02; 49.83]CheckMate 026 (PDL1>1%), 201610%530NAnot evaluable Myalgia TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80] 1.94[0.06; 57.80]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Myocarditis TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80] 1.94[0.06; 57.80]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Myositis TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] 0.97[0.02; 49.41]KEYNOTE-024 (PDL1>50%), 201610%304NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.19 [0.02; 1.67] KEYNOTE-024 (PDL1>50%), 2016 0.16 [0.01; 3.21] KEYNOTE-042 (PDL1>1%), 2019 0.07 [0.00; 1.21] 0.14[0.03; 0.62]CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201930%2,085moderatenot evaluable Nephritis TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69] KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80] 1.94[0.18; 21.52]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Neutropenia TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.02 [0.00; 0.25] KEYNOTE-024 (PDL1>50%), 2016 0.02 [0.00; 0.35] KEYNOTE-042 (PDL1>1%), 2019 0.02 [0.00; 0.14] 0.02[0.00; 0.08]CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201930%2,085moderatenot evaluable Pancreatitis TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69] KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81] 1.44[0.11; 18.87]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Peripheral neuropathy TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83] KEYNOTE-042 (PDL1>1%), 2019 0.10 [0.01; 1.76] 0.22[0.02; 2.27]CheckMate 026 (PDL1>1%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,781moderatenot evaluable Peripheral oedema TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83] 0.98[0.02; 49.83]CheckMate 026 (PDL1>1%), 201610%530NAnot evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 0.08 [0.00; 1.43] 0.08[0.00; 1.43]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36] KEYNOTE-024 (PDL1>50%), 2016 3.97 [0.44; 35.97] KEYNOTE-042 (PDL1>1%), 2019 20.97 [2.81; 156.36] 8.21[2.15; 31.32]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201930%2,104moderatenot evaluable Pruritus TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72] KEYNOTE-042 (PDL1>1%), 2019 3.88 [0.17; 86.15] 1.52[0.15; 15.00]CheckMate 026 (PDL1>1%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,781moderatenot evaluable Pyrexia TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72] KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] 0.66[0.05; 8.61]CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 201620%834moderatenot evaluable Rash TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 1.98 [0.18; 21.94] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.38 [0.23; 8.34] KEYNOTE-042 (PDL1>1%), 2019 5.82 [0.29; 116.52] 2.01[0.55; 7.36]CheckMate 026 (PDL1>1%), 2016, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-042 (PDL1>1%), 201930%2,330moderatenot evaluable Renal and urinary disorders TRAE (grade 3-4) detailed resultsCheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09] 1.97[0.07; 59.09]CheckMate 026 (PDL1>1%), 201610%530NAnot evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed resultsCheckMate 026 (PDL1>1%), 2016 12.07 [0.67; 217.19] 12.07[0.67; 217.19]CheckMate 026 (PDL1>1%), 201610%530NAnot evaluable Severe skin reaction TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 12.12 [0.67; 218.98] KEYNOTE-042 (PDL1>1%), 2019 10.81 [1.39; 83.96] 11.23[2.11; 59.83]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed resultsCheckMate 026 (PDL1>1%), 2016 5.00 [0.58; 43.09] 5.00[0.58; 43.09]CheckMate 026 (PDL1>1%), 201610%530NAnot evaluable Stomatitis TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72] KEYNOTE-024 (PDL1>50%), 2016 0.24 [0.01; 5.39] KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81] 0.44[0.06; 3.17]CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201930%2,085moderatenot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.04 [0.01; 0.31] KEYNOTE-024 (PDL1>50%), 2016 0.06 [0.00; 1.02] KEYNOTE-042 (PDL1>1%), 2019 0.10 [0.01; 0.75] 0.06[0.02; 0.22]CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201930%2,085moderatenot evaluable Thyroiditis TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81] 0.97[0.06; 15.56]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Vomiting TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.10 [0.01; 1.78] KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.06; 15.71] KEYNOTE-042 (PDL1>1%), 2019 0.24 [0.01; 5.36] 0.30[0.05; 1.60]CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201930%2,085moderatenot evaluable Anaemia AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.08 [0.03; 0.20] KEYNOTE-598, 2020 1.14 [0.41; 3.20] 0.30[0.02; 4.07]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-598, 2020293%1,112moderatenot evaluable Arthralgia AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 2.01 [0.36; 11.05] 2.01[0.36; 11.05]KEYNOTE-598, 202010%563NAnot evaluable Asthenia AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.36 [0.07; 1.89] KEYNOTE-598, 2020 0.25 [0.03; 2.22] 0.32[0.08; 1.18]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-598, 202020%1,112moderatenot evaluable Back pain AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 0.50 [0.04; 5.51] 0.50[0.04; 5.51]KEYNOTE-598, 202010%563NAnot evaluable Constipation AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.38 [0.23; 8.34] KEYNOTE-598, 2020 1.00 [0.14; 7.12] 1.19[0.32; 4.49]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-598, 202020%1,112moderatenot evaluable Cough AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.84 [0.06; 55.14] KEYNOTE-598, 2020 0.50 [0.02; 14.89] 0.96[0.09; 10.59]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-598, 202020%1,112lownot evaluable Decreased appetite AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36] KEYNOTE-598, 2020 6.03 [0.30; 120.98] 4.76[0.55; 41.15]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-598, 202020%1,112lownot evaluable Diarrhoea AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.23 [0.01; 5.09] KEYNOTE-598, 2020 10.29 [1.31; 80.96] 1.84[0.04; 75.61]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-598, 2020275%1,112lownot evaluable Dyspnoea AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36] KEYNOTE-598, 2020 0.87 [0.31; 2.43] 1.00[0.38; 2.66]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-598, 202020%1,112lownot evaluable Fatigue AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.30 [0.06; 1.51] KEYNOTE-598, 2020 1.51 [0.42; 5.39] 0.73[0.15; 3.49]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-598, 2020258%1,112lownot evaluable Febrile neutropenia AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.05 [0.00; 0.86] 0.05[0.00; 0.86]IMpower-110 (TC1/2/3 or IC1/2/3), 202010%549NAnot evaluable Hypertension AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.61 [0.10; 3.68] 0.61[0.10; 3.68]IMpower-110 (TC1/2/3 or IC1/2/3), 202010%549NAnot evaluable Hypothyroidism AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 1.00 [0.06; 16.01] 1.00[0.06; 16.01]KEYNOTE-598, 202010%563NAnot evaluable Increase AST AE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 7.05 [0.86; 57.74] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 4.66 [0.54; 40.17] KEYNOTE-598, 2020 2.52 [0.48; 13.09] 3.96[1.30; 12.02]CheckMate 026 (PDL1>1%), 2016, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-598, 202030%1,642moderatenot evaluable Increased ALT AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 4.66 [0.54; 40.17] KEYNOTE-598, 2020 2.28 [0.69; 7.50] 2.70[0.95; 7.64]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-598, 202020%1,112lownot evaluable Leucopenia AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.23 [0.03; 2.05] 0.23[0.03; 2.05]IMpower-110 (TC1/2/3 or IC1/2/3), 202010%549NAnot evaluable Nausea AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.18 [0.02; 1.56] KEYNOTE-598, 2020 4.01 [0.18; 89.26] 0.69[0.03; 13.97]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-598, 2020261%1,112moderatenot evaluable Neutropenia AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.03 [0.01; 0.14] 0.03[0.01; 0.14]IMpower-110 (TC1/2/3 or IC1/2/3), 202010%549NAnot evaluable Pancytopenia (AE grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.46 [0.04; 5.08] 0.46[0.04; 5.08]IMpower-110 (TC1/2/3 or IC1/2/3), 202010%549NAnot evaluable Pneumonia AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.71 [0.26; 1.93] KEYNOTE-598, 2020 1.36 [0.72; 2.56] 1.11[0.61; 2.00]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-598, 2020214%1,112lownot evaluable Pneumonitis AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 2.21 [0.83; 5.91] 2.21[0.83; 5.91]KEYNOTE-598, 202010%563NAnot evaluable Pruritus AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 0.50 [0.04; 5.51] 0.50[0.04; 5.51]KEYNOTE-598, 202010%563NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.46 [0.02; 13.73] KEYNOTE-598, 2020 6.03 [0.30; 120.98] 1.89[0.15; 23.34]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-598, 2020219%1,112lownot evaluable Rash AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 16.38 [0.94; 286.59] 16.38[0.94; 286.59]KEYNOTE-598, 202010%563NAnot evaluable Sepsis AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.46 [0.04; 5.08] 0.46[0.04; 5.08]IMpower-110 (TC1/2/3 or IC1/2/3), 202010%549NAnot evaluable Thrombocytopenia AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.05 [0.01; 0.34] 0.05[0.01; 0.34]IMpower-110 (TC1/2/3 or IC1/2/3), 202010%549NAnot evaluable Vomiting AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.46 [0.04; 5.08] KEYNOTE-598, 2020 4.03 [0.45; 36.27] 1.44[0.17; 12.08]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-598, 2020242%1,112lownot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-04-28 22:40 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 171 - treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons